A month ago the Lancet and the New England Journal of Medicine each retracted a major study on Covid-19 drug therapies. One article had been up for more than a month, the other for less than two weeks. Both were based on faked data. That the rush to publish on Covid-19 led established researchers, reviewers and journals to skip elementary checks is deplorable, if not entirely surprising.
Already a subscriber? Log in
Get 10 issues
for $10
Subscribe to The Spectator Australia today for the next 10 magazine issues, plus full online access, for just $10.
- Delivery of the weekly magazine
- Unlimited access to spectator.com.au and app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Unlock this article
You might disagree with half of it, but you’ll enjoy reading all of it. Try your first month for free, then just $2 a week for the remainder of your first year.
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in